Amoeba SA stock analysis
Want to see FR:ALMIB full AI Analyst Report?
Amoeba SA (ALMIB) Stock Price & Analysis
ALMIB Stock Chart & Stats
- Day’s Range
- EUR 0.28 - EUR 0.32
- 52-Week Range
- EUR 0.25 - EUR 1.12
- Previous Close
- EUR 0.29
- Volume
- N/A
- Average Volume (3M)
- 593.92K
- Market Cap
- EUR 40.10M
- Enterprise Value
- EUR 78.49M
- Total Cash (Recent Filing)
- EUR 5.52M
- Total Debt (Recent Filing)
- EUR 12.67M
- Price to Earnings (P/E)
- ―
- Beta
- 1.24
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Biotechnology Platform
A proprietary biological platform gives Amoéba a defined foundation for developing multiple products across crop protection and industrial applications. If regulatory and commercial execution progress, the same underlying technology could support broader product expansion over the next several quarters.
Diversified Application Potential
Amoéba is pursuing more than one end market, spanning sustainable agriculture and industrial bio-based applications. This broadens the potential commercial opportunity for its technology and may reduce dependence on a single product category if launches and approvals advance.
Reduced Losses And Cash Burn
Although performance remains weak, the narrowing of operating losses and improvement in free cash flow indicate some movement toward better financial control. Sustaining this direction could extend the company’s funding runway and improve the feasibility of scaling its platform.
Bears Say
Revenue Collapse
Revenue falling to zero shows that the business has not yet established dependable commercial traction. Without recurring sales, Amoéba cannot demonstrate durable market adoption or generate an internal funding source for continued research, regulatory work, and commercialization.
Negative Equity And Rising Debt
Negative equity combined with materially higher debt weakens financial flexibility and increases dependence on refinancing or additional capital. This structure can constrain investment in the platform and leaves the company less able to absorb delays in commercialization or regulatory progress.
Persistent Cash Burn
Consistently negative operating and free cash flow means current activities are not self-funding. Continued cash consumption may require external financing to maintain operations and investment, creating dilution or refinancing pressure while revenue remains unproven.
Amoeba SA News
ALMIB FAQ
What was Amoeba SA’s price range in the past 12 months?
What is Amoeba SA’s market cap?
When is Amoeba SA’s upcoming earnings report date?
How were Amoeba SA’s earnings last quarter?
Is Amoeba SA overvalued?
Does Amoeba SA pay dividends?
What is Amoeba SA’s EPS estimate?
How many shares outstanding does Amoeba SA have?
What happened to Amoeba SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Amoeba SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.
- Sector
- General
- Industry
- Agricultural Inputs
- CEO
- Jean-Francois Doucet
- Employees
- 23
- Website
- amoeba-nature.com
- Address
- 38 Avenue de FrEres Montgolfier, Chassieu, AR, 69680, FR
Amoeba SA (ALMIB) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 11 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 6 | 0 | 6 |









